Dalila C Pinto, PhD
- ASSISTANT PROFESSOR | Psychiatry
- ASSISTANT PROFESSOR | Genetics and Genomic Sciences
Research Topics:Autism, Bioinformatics, Chromatin, Computational Biology, Epilepsy, Gene Discovery, Gene Expressions, Gene Regulation, Genetics, Genomics, Mental Retardation, Microarray, Transcription Factors
Dr. Pinto is an Assistant Professor of Psychiatry, Genetics and Genomic Sciences, and a faculty member of the Icahn Genomics Insttitute. Dr. Pinto’s laboratory focuses on identifying genes and biological pathways involved in various neurodevelopmental disorders, including autism, intellectual disability, epilepsy, and rett syndrome-like phenotypes. Dr. Pinto integrates various forms of genetic variation (deletions, duplications, indels, single-point mutations), with gene expression, epigenetics and clinical data, using a combination of innovative high-throughput experimental and bioinformatics approaches, that altogether could implicate novel risk factors and provide insights into the mechanisms underlying these disorders. Dr. Pinto’s laboratory also works with worldwide clinical collaborators that are responsible for patients and families recruitment and phenotypic examination.
Multi-Disciplinary Training AreasArtificial Intelligence and Emerging Technologies in Medicine [AIET], Genetics and Genomic Sciences [GGS], Neuroscience [NEU]
MSc, MSc, University of Porto
PhD, University of Utrecht
Postdoctoral, Hospital for Sick Children Toronto
For more information see the Pinto Lab website.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Pinto did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.